吡格列酮
二甲双胍
医学
脂肪肝
内科学
胃肠病学
维生素
糖尿病
随机对照试验
2型糖尿病
内分泌学
疾病
胰岛素
作者
Manouchehr Khoshbaten,Samineh Beheshtirouy,Shahrzad Shayanrad,Afshin Gharekhani,Haleh Rezaee
出处
期刊:Drug research
[Thieme Medical Publishers (Germany)]
日期:2023-02-15
卷期号:73 (04): 232-237
被引量:1
摘要
Abstract Background This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease. Methods A randomized controlled clinical trial was designed with 68 patients diagnosed with non-alcoholic fatty liver disease by sonography and clinical examinations. Sixty-eight patients were randomly divided into two groups; 34 were assigned to receive 15 mg of pioglitazone per day and 34 were assigned to receive 1000 mg of metformin per day for 6 months. All of the patients received vitamin E at a dose of 800 IU daily for six months. The sonography grade of fatty liver and the levels of alanine aminotransferase and aspartate aminotransferase of patients were evaluated at baseline, and within three and six months after initiation of the intervention. Results The use of metformin or pioglitazone in combination with vitamin E decreased the sonography grade of non-alcoholic fatty liver disease patients after 6 months of treatment (p-value<0.05); however, patients in metformin group benefit more compared to pioglitazone group. Patients who received metformin and vitamin E had a significant reduction in the levels of alanine aminotransferase and aspartate aminotransferase (p-value<0.05). There were no significant changes in the liver enzymes level of the patients who received pioglitazone and vitamin E (p-value>0.05). Major conclusion The concomitant use of metformin and vitamin E significantly improves the sonography grade of fatty liver and the level of liver enzymes in patients with non-alcoholic fatty liver disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI